title: Differential effects of selective adenosine antagonists on the effort-related impairments induced by dopamine D1 and D2 antagonism.
abstract: Mesolimbic dopamine (DA) is a critical component of the brain circuitry regulating behavioral activation and effort-related processes. Rats with impaired DA transmission reallocate their instrumental behavior away from food-reinforced tasks with high response requirements, and instead select less effortful food-seeking behaviors. Previous work showed that adenosine A(2A) antagonists can reverse the effects of DA D(2) antagonists on effort-related choice. However, less is known about the effects of adenosine A(1) antagonists. Despite anatomical data showing that A(1) and D(1) receptors are co-localized on the same striatal neurons, it is uncertain if A(1) antagonists can reverse the effects DA D(1) antagonists. The present work systematically compared the ability of adenosine A(1) and A(2A) receptor antagonists to reverse the effects of DA D(1) and D(2) antagonists on a concurrent lever pressing/feeding choice task. With this procedure, rats can choose between responding on a fixed ratio 5 lever-pressing schedule for a highly preferred food (i.e. high carbohydrate pellets) vs. approaching and consuming a less preferred rodent chow. The D(1) antagonist ecopipam (0.2 mg/kg i.p.) and the D(2) antagonist eticlopride (0.08 mg/kg i.p.) altered choice behavior, reducing lever pressing and increasing lab chow intake. Co-administration of the adenosine A(1) receptor antagonists 8-cyclopentyl-1,3-dipropylxanthine (DPCPX; 0.375, 0.75, and 1.5 mg/kg i.p.), and 8-cyclopentyltheophylline (CPT; 3.0, 6.0, 12.0 mg/kg i.p.) failed to reverse the effects of either the D(1) or D(2) antagonist. In contrast, the adenosine A(2A) antagonist KW-6002 (0.125, 0.25 and 0.5 mg/kg i.p.) was able to produce a robust reversal of the effects of eticlopride, as well as a mild partial reversal of the effects of ecopipam. Adenosine A(2A) and DA D(2) receptors interact to regulate effort-related choice behavior, which may have implications for the treatment of psychiatric symptoms such as psychomotor slowing, fatigue or anergia that can be observed in depression and other disorders.
authors.affiliation: Department of Psychology, University of Connecticut, Storrs, CT 06269-1020, USA.
authors.forename: E J
authors.initials: EJ
authors.lastname: Nunes
authors.forename: P A
authors.initials: PA
authors.lastname: Randall
authors.forename: J L
authors.initials: JL
authors.lastname: Santerre
authors.forename: A B
authors.initials: AB
authors.lastname: Given
authors.forename: T N
authors.initials: TN
authors.lastname: Sager
authors.forename: M
authors.initials: M
authors.lastname: Correa
authors.forename: J D
authors.initials: JD
authors.lastname: Salamone
mesh_terms: D000818:Animals; D018492:Dopamine Antagonists / Q000494:pharmacology*; D065127:Dopamine D2 Receptor Antagonists; D004305:Dose-Response Relationship, Drug; D005247:Feeding Behavior / Q000187:drug effects* / Q000502:physiology; D008297:Male; D011597:Psychomotor Performance / Q000187:drug effects* / Q000502:physiology; D058915:Purinergic P1 Receptor Antagonists / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors* / Q000502:physiology; D017448:Receptors, Dopamine D2 / Q000502:physiology; D012055:Reinforcement Schedule
chemical_list: D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D058915:Purinergic P1 Receptor Antagonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2